Showing results (211-220 of 225) with videos related to
Sort By:
Pageof 23
Neurology (E-Cronicon)|September 29, 2025
Multi-Locus Pro-Dopaminergic Restoration of Reward Brain Circuitry in Reward Deficiency Rescinds Mono-Pharmaceutical TargetingKenneth Blum, Kavya Mohankumar, Debasis Bagchi, et al.Gene & Protein in Disease|August 1, 2025
Exploring dopamine as the master regulator of brain circuitry and mental health genomeKenneth Blum, Eric R Braverman, Alireza Sharafshah, et al.Psychology Research and Behavior Management|December 5, 2023
Neurogenetics and Epigenetics of LonelinessAbdalla Bowirrat, Igor Elman, Catherine A Dennen, et al.Open Journal of Immunology|November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial TherapiesKenneth Blum, Igor Elman, David Han, et al.Frontiers in Public Health|December 3, 2025
Correction: Targeting pro-dopaminergic agonism to attenuate depression in patients displaying genetic/epigenetic predisposition to hypodopaminergiaKai-Uwe Lewandrowski, Kenneth Blum, Alexander P L Lewandrowski, et al.Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.Psychiatric Research and Clinical Practice|October 18, 2022
Trajectories of Depressive and Anxiety Symptoms Across Pregnancy and Postpartum in Selective Serotonin Reuptake Inhibitor-Treated WomenGabrielle A Mesches, Jody D Ciolino, Catherine S Stika, et al.Acta Scientific Neurology|September 2, 2025
Dopaminergic Homeostatic Therapy (DHT™) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS®) ScreeningKai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.Gene & Protein in Disease|May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequencesKenneth Blum, Abdalla Bowirrat, David Baron, et al.Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.Pageof 23